Rare Blood Types Due To Genetic Variation
|
By LabMedica International staff writers Posted on 15 Mar 2012 |
Blood group typing is a routine procedure before blood transfusion, but some blood types, such as Langereis and Junior, are exceedingly rare worldwide.
While blood transfusion problems due to Langereis and Junior blood types are uncommon, several ethnic populations, such as certain Japanese populations and European Gypsies, are at risk.
An international team working with the University of Vermont (Burlington, VT, USA) used a multiplicity of analytical techniques including flow cytometry, immunofluorescence microscopy, mass spectrometry, and sequencing to identify the genetic basis of the Langereis blood group.
The scientists identified the human adenosine triphosphate (ATP)-binding cassette (ABC) transporter ABCB6 as the genetic basis of the Langereis blood group antigen expressed on red blood cells, but also at the plasma membrane of hepatocellular carcinoma (HCC) cells, and established that ABCB6 encodes a new blood group system (Langereis, Lan). Targeted sequencing of ABCB6 in 12 unrelated individuals of the Lan(−) blood type identified 10 different ABCB6 null mutations.
A Lan-specific monoclonal antibody has been developed and will greatly facilitate the identification of Lan(−) blood donors. In elucidating the genetic basis of the Lan(−) blood type, the scientists have uncovered ten null mutations of ABCB6. It will be necessary to closely monitor Lan(−) (ABCB6−/−) individuals, especially those treated with drugs potentially transported by ABCB6, because this deficiency may alter the pharmacokinetics of these drugs or result in adverse effects such as hepatotoxity. The authors concluded that transfusion support of individuals with an anti-Lan antibody is highly challenging partly because of the scarcity of compatible blood donors, but mainly because of the lack of reliable reagents for blood screening
Junior-negative blood donors are extremely rare too, but that may soon change. Bryan Ballif, PhD, an assistant professor at the University of Vermont and an author of the study said, "We're following up on more unknown blood types. There are probably on the order of 10 to 15 more of these unknown blood type systems, where we know there is a problem but we don't know what the protein is that is causing the problem. More than 50,000 Japanese are thought to be Junior negative and may encounter blood transfusion problems or mother-fetus incompatibility."
The study was published in the February 2012 issue of Nature Genetics.
Related Links:
University of Vermont
While blood transfusion problems due to Langereis and Junior blood types are uncommon, several ethnic populations, such as certain Japanese populations and European Gypsies, are at risk.
An international team working with the University of Vermont (Burlington, VT, USA) used a multiplicity of analytical techniques including flow cytometry, immunofluorescence microscopy, mass spectrometry, and sequencing to identify the genetic basis of the Langereis blood group.
The scientists identified the human adenosine triphosphate (ATP)-binding cassette (ABC) transporter ABCB6 as the genetic basis of the Langereis blood group antigen expressed on red blood cells, but also at the plasma membrane of hepatocellular carcinoma (HCC) cells, and established that ABCB6 encodes a new blood group system (Langereis, Lan). Targeted sequencing of ABCB6 in 12 unrelated individuals of the Lan(−) blood type identified 10 different ABCB6 null mutations.
A Lan-specific monoclonal antibody has been developed and will greatly facilitate the identification of Lan(−) blood donors. In elucidating the genetic basis of the Lan(−) blood type, the scientists have uncovered ten null mutations of ABCB6. It will be necessary to closely monitor Lan(−) (ABCB6−/−) individuals, especially those treated with drugs potentially transported by ABCB6, because this deficiency may alter the pharmacokinetics of these drugs or result in adverse effects such as hepatotoxity. The authors concluded that transfusion support of individuals with an anti-Lan antibody is highly challenging partly because of the scarcity of compatible blood donors, but mainly because of the lack of reliable reagents for blood screening
Junior-negative blood donors are extremely rare too, but that may soon change. Bryan Ballif, PhD, an assistant professor at the University of Vermont and an author of the study said, "We're following up on more unknown blood types. There are probably on the order of 10 to 15 more of these unknown blood type systems, where we know there is a problem but we don't know what the protein is that is causing the problem. More than 50,000 Japanese are thought to be Junior negative and may encounter blood transfusion problems or mother-fetus incompatibility."
The study was published in the February 2012 issue of Nature Genetics.
Related Links:
University of Vermont
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








